Geary Timothy G, Thompson David P
Pfizer Animal Health, 7000 Portage Road, Kalamazoo, MI 49001, USA.
Vet Parasitol. 2003 Jul 25;115(2):167-84. doi: 10.1016/s0304-4017(03)00205-x.
Prospects for discovering new antiparasitic drugs for veterinary medicine in the coming century will be determined by economic, social and scientific factors. Consolidation in the pharmaceutical industry in general, and the animal health industry in particular, changes the business conditions in which drug discovery for veterinary medicine occurs. Social pressures on traditional animal agriculture and companion animal ownership have shifted the interest of animal companies primarily to pet medicine. Antiparasitic drug discovery is more than ever targeted to the most lucrative market segments, but the excellence of available drugs, and the apparent lack of resistance in important parasites, reduces industrial motivation to invest in parasitology. Veterinary parasitologists in academia will still have the chance to interact with their industrial counterparts in the traditional ways of supporting drug discovery and development. Nonetheless, there are many new opportunities to expand the research horizons of veterinary parasitology to strengthen the case for retaining a significant presence in the animal health industry.
下个世纪发现新型兽用抗寄生虫药物的前景将由经济、社会和科学因素决定。整个制药行业,尤其是动物保健行业的整合,改变了兽用药物研发的商业环境。传统畜牧业和伴侣动物饲养面临的社会压力,已使动物保健公司的兴趣主要转向宠物药。抗寄生虫药物研发比以往任何时候都更侧重于最有利可图的市场领域,但现有药物的卓越性以及重要寄生虫中明显缺乏抗药性,降低了行业投资寄生虫学研究的积极性。学术界的兽医寄生虫学家仍有机会以支持药物研发的传统方式与行业同行互动。尽管如此,仍有许多新机会来拓展兽医寄生虫学的研究视野,以增强在动物保健行业保持重要地位的理由。